Loading stock data…
$0.90-0.07 (-7.02%)
Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors.
Pliant Therapeutics, Inc. in the Healthcare sector is trading at $0.90 with a market capitalization of $72M. Wall Street consensus targets $2.00 (1 analysts), implying a +122.2% move over the next 12 months. The stock is currently near its 52-week low of $0.90, remaining 24.4% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 10 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$23.86M↓ | -$21.77M↑ | -$23.58M↑ | -$28.27M↑ | -$45.59M |
| Net Income | -$22.37M↓ | -$20.04M↑ | -$23.58M↑ | -$26.30M↑ | -$43.30M |
Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecul...